iAbeta5Alternative Names: 5 amino acid β-sheet breaker peptide; Amyloid inhibiting peptides; iAβ5; β-Sheet breaker peptide
Latest Information Update: 28 Jan 2005
At a glance
- Originator New York University; TorreyPines Therapeutics Inc
- Mechanism of Action Amyloid inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease